Deep Track Capital, LP
Filing Date
Global Rank
#684
/ 8,622
▲ 105
· as of Mar 2026
Top Industry
Biotechnology
86.4%
3Y Alpha vs SPY
+11.6%
Period ended 4 months ago
Filed May 15, 2026 · 2mo
18 quarters · since Dec 2021
Clone Performance
Jul 2023–Jul 2026 · vs SPYHypothetical growth of buying every stock this filer reported holding, rebalancing on each filing and indexed to the same start. Option positions cannot be bought this way and are left out.
Cloned portfolio
+121.9%
SPY
+67.9%
Annualised alpha
+11.6%
Max drawdown
−50.6%
Estimate. 13F holdings are quarter-lagged, so the clone rebalances about 45 days after each period end — when the filing becomes public — and it excludes option and short positions. It tracks 99% of reported value on average across 13 quarters. Past performance does not predict future results.
Portfolio Concentration
62 tracked positions · as of Mar 31, 2026 · Δ vs Dec 31, 2025Top Position
6.4%
−0.8 pts
Top 5
26.9%
−5.4 pts
Top 10
44.4%
−10.0 pts
HHI
300
Diversified−95
Portfolio Trend
18 quarters · across all stocks
Sector Breakdown
As of Mar 31, 2026| Sector | % Portfolio | Value |
|---|---|---|
| Healthcare | 100.0% | $4,846,263,139 |
Last Quarter's Activity
Export CSVAdded To
Positions the filer increased
23 positions
| Ticker | Company | Δ Shares | Shares | Value | Open |
|---|---|---|---|---|---|
| OCUL | Ocular Therapeutix, Inc | +11,615,868 | 19,686,282 | $166,742,808 | |
| CMPS | COMPASS Pathways plc | +4,827,173 | 12,161,496 | $67,253,072 | |
| MLTX | MoonLake Immunotherapeutics | +1,798,792 | 6,408,863 | $119,461,206 | |
| ALKS | Alkermes plc. | +1,590,323 | 3,590,323 | $126,953,821 | |
| BCAX | Bicara Therapeutics Inc. | +1,448,496 | 4,062,500 | $80,803,125 | |
| XFOR | X4 Pharmaceuticals, Inc | +1,325,874 | 6,339,535 | $26,182,279 | |
| VERA | Vera Therapeutics, Inc. | +1,284,932 | 4,106,067 | $165,187,075 | |
| CNTA | Centessa Pharmaceuticals plc | +1,158,041 | 3,158,041 | $125,437,388 | |
| JANX | Janux Therapeutics, Inc. | +1,097,701 | 1,187,290 | $16,503,331 | |
| CRMD | CorMedix Inc. | +1,000,000 | 6,274,076 | $42,600,976 | |
| IVA | Inventiva S.A. | +732,453 | 1,222,453 | $6,784,614 | |
| GRAL | GRAIL, Inc. | +700,000 | 1,722,797 | $89,034,148 | |
| TARS | Tarsus Pharmaceuticals, Inc. | +595,966 | 3,600,000 | $252,540,000 | |
| COGT | Cogent Biosciences, Inc. | +546,898 | 1,000,000 | $38,490,000 | |
| GH | Guardant Health, Inc. | +538,241 | 3,338,241 | $308,353,321 | |
| TERN | Terns Pharmaceuticals, Inc. | +304,829 | 1,073,877 | $56,614,795 | |
| PCVX | Vaxcyte, Inc. | +300,000 | 4,300,000 | $249,873,000 | |
| TNGX | Tango Therapeutics, Inc. | +295,438 | 2,750,000 | $57,530,000 | |
| IONS | Ionis Pharmaceuticals Inc | +250,000 | 1,950,000 | $146,425,500 | |
| GPCR | Structure Therapeutics Inc. | +168,066 | 4,279,848 | $206,288,673 | |
| ANIP | Ani Pharmaceuticals Inc | +122,316 | 600,000 | $46,140,000 | |
| SLNO | Soleno Therapeutics Inc | +78,710 | 1,078,710 | $36,115,210 | |
| BBIO | BridgeBio Pharma, Inc. | +31,303 | 841,445 | $62,485,705 | |
| No positions match the current search. | |||||
Trimmed
Positions the filer reduced
14 positions
| Ticker | Company | Δ Shares | Shares | Value | Open |
|---|---|---|---|---|---|
| APLS | Apellis Pharmaceuticals, Inc. | −3,217,626 | 4,532,374 | $182,337,406 | |
| CYTK | Cytokinetics Inc | −1,962,678 | 1,374,320 | $90,581,431 | |
| BMRN | Biomarin Pharmaceutical Inc | −1,150,000 | 1,150,000 | $64,963,500 | |
| VRDN | Viridian Therapeutics, Inc.\DE | −1,130,889 | 1,393,944 | $27,265,544 | |
| GERN | Geron Corp | −790,993 | 31,720,278 | $47,263,214 | |
| MAZE | Maze Therapeutics, Inc. | −768,878 | 3,477,562 | $103,805,225 | |
| NRIX | Nurix Therapeutics, Inc. | −691,211 | 6,345,244 | $98,351,282 | |
| DYN | Dyne Therapeutics, Inc. | −650,000 | 2,000,000 | $36,260,000 | |
| CLDX | Celldex Therapeutics, Inc. | −616,759 | 1,283,979 | $40,727,813 | |
| HELP | Cybin Inc. | −541,118 | 1,313,137 | $6,303,057 | |
| MBX | MBX Biosciences, Inc. | −492,221 | 2,757,569 | $82,313,434 | |
| ORKA | Oruka Therapeutics, Inc. | −127,307 | 2,034,203 | $99,777,657 | |
| IMCR | Immunocore Holdings plc | −72,094 | 1,931,884 | $58,246,302 | |
| AXSM | Axsome Therapeutics, Inc. | −50,000 | 1,100,000 | $185,922,000 | |
| No positions match the current search. | |||||
New Positions
Positions the filer opened this quarter
16 positions
| Ticker | Company | Shares | Value | Open |
|---|---|---|---|---|
| ALMS | Alumis Inc. | 6,772,595 | $149,200,267 | |
| NUVL | Nuvalent, Inc. | 1,376,324 | $141,004,393 | |
| GMAB | Genmab A/S | 3,663,250 | $98,284,997 | |
| DFTX | Definium Therapeutics, Inc. | 3,000,000 | $56,700,000 | |
| ATAI | AtaiBeckley Inc. | 12,000,000 | $42,480,000 | |
| CRVS | Corvus Pharmaceuticals, Inc. | 2,491,539 | $36,451,215 | |
| ACRS | Aclaris Therapeutics, Inc. | 9,345,000 | $35,043,750 | |
| MANE | Veradermics, Inc | 500,000 | $31,575,000 | |
| SLDB | Solid Biosciences Inc. | 3,565,062 | $25,668,446 | |
| APGE | Apogee Therapeutics, Inc. | 285,000 | $23,988,450 | |
| KURA | Kura Oncology, Inc. | 2,643,542 | $21,491,996 | |
| IPSC | Century Therapeutics, Inc. | 9,487,745 | $21,442,303 | |
| BEAM | Beam Therapeutics Inc. | 820,765 | $19,558,829 | |
| PSNL | Personalis, Inc. | 3,000,000 | $19,110,000 | |
| PMN | ProMIS Neurosciences Inc. | 835,655 | $10,612,818 | |
| LRMR | Larimar Therapeutics, Inc. | 1,500,000 | $6,750,000 | |
| No positions match the current search. | ||||
62 tracked positions ·
$4,846,263,139 total
· as of Mar 31, 2026
Showing 1–50
of 62 positions by value
· page 1 of 2
| Ticker | Company | Type | Shares | Value (USD) | % of Portfolio | History |
|---|---|---|---|---|---|---|
| GH |
Guardant Health, Inc.
Healthcare
|
Added | 3,338,241 | $308,353,321 | 6.36% | |
| IMVT |
Immunovant, Inc.
Healthcare
|
Held | 11,526,971 | $286,329,959 | 5.91% | |
| TARS |
Tarsus Pharmaceuticals, Inc.
Healthcare
|
Added | 3,600,000 | $252,540,000 | 5.21% | |
| PCVX |
Vaxcyte, Inc.
Healthcare
|
Added | 4,300,000 | $249,873,000 | 5.16% | |
| GPCR |
Structure Therapeutics Inc.
Healthcare
|
Added | 4,279,848 | $206,288,673 | 4.26% | |
| AXSM |
Axsome Therapeutics, Inc.
Healthcare
|
Reduced | 1,100,000 | $185,922,000 | 3.84% | |
| APLS |
Apellis Pharmaceuticals, Inc.
Healthcare
|
Reduced | 4,532,374 | $182,337,406 | 3.76% | |
| OCUL |
Ocular Therapeutix, Inc
Healthcare
|
Added | 19,686,282 | $166,742,808 | 3.44% | |
| VERA |
Vera Therapeutics, Inc.
Healthcare
|
Added | 4,106,067 | $165,187,075 | 3.41% | |
| ALMS |
Alumis Inc.
Healthcare
|
NEW | 6,772,595 | $149,200,267 | 3.08% | |
| IONS |
Ionis Pharmaceuticals Inc
Healthcare
|
Added | 1,950,000 | $146,425,500 | 3.02% | |
| NUVL |
Nuvalent, Inc.
Healthcare
|
NEW | 1,376,324 | $141,004,393 | 2.91% | |
| ALKS |
Alkermes plc.
Healthcare
|
Added | 3,590,323 | $126,953,821 | 2.62% | |
| CNTA |
Centessa Pharmaceuticals plc
Healthcare
|
Added | 3,158,041 | $125,437,388 | 2.59% | |
| MLTX |
MoonLake Immunotherapeutics
Healthcare
|
Added | 6,408,863 | $119,461,206 | 2.47% | |
| MAZE |
Maze Therapeutics, Inc.
Healthcare
|
Reduced | 3,477,562 | $103,805,225 | 2.14% | |
| ORKA |
Oruka Therapeutics, Inc.
Healthcare
|
Reduced | 2,034,203 | $99,777,657 | 2.06% | |
| NRIX |
Nurix Therapeutics, Inc.
Healthcare
|
Reduced | 6,345,244 | $98,351,282 | 2.03% | |
| GMAB |
Genmab A/S
Healthcare
|
NEW | 3,663,250 | $98,284,997 | 2.03% | |
| CYTK |
Cytokinetics Inc
Healthcare
|
Reduced | 1,374,320 | $90,581,431 | 1.87% | |
| GRAL |
GRAIL, Inc.
Healthcare
|
Added | 1,722,797 | $89,034,148 | 1.84% | |
| LBRX |
Lb Pharmaceuticals Inc
Healthcare
|
Held | 3,352,804 | $82,680,146 | 1.71% | |
| MBX |
MBX Biosciences, Inc.
Healthcare
|
Reduced | 2,757,569 | $82,313,434 | 1.70% | |
| BCAX |
Bicara Therapeutics Inc.
Healthcare
|
Added | 4,062,500 | $80,803,125 | 1.67% | |
| CMPS |
COMPASS Pathways plc
Healthcare
|
Added | 12,161,496 | $67,253,072 | 1.39% | |
| BMRN |
Biomarin Pharmaceutical Inc
Healthcare
|
Reduced | 1,150,000 | $64,963,500 | 1.34% | |
| BBIO |
BridgeBio Pharma, Inc.
Healthcare
|
Added | 841,445 | $62,485,705 | 1.29% | |
| IMCR |
Immunocore Holdings plc
Healthcare
|
Reduced | 1,931,884 | $58,246,302 | 1.20% | |
| TNGX |
Tango Therapeutics, Inc.
Healthcare
|
Added | 2,750,000 | $57,530,000 | 1.19% | |
| DFTX |
Definium Therapeutics, Inc.
Healthcare
|
NEW | 3,000,000 | $56,700,000 | 1.17% | |
| TERN |
Terns Pharmaceuticals, Inc.
Healthcare
|
Reduced | 1,073,877 | $56,614,795 | 1.17% | |
| GERN |
Geron Corp
Healthcare
|
Reduced | 31,720,278 | $47,263,214 | 0.98% | |
| ANIP |
Ani Pharmaceuticals Inc
Healthcare
|
Added | 600,000 | $46,140,000 | 0.95% | |
| CRMD |
CorMedix Inc.
Healthcare
|
Added | 6,274,076 | $42,600,976 | 0.88% | |
| ATAI |
AtaiBeckley Inc.
Healthcare
|
NEW | 12,000,000 | $42,480,000 | 0.88% | |
| CLDX |
Celldex Therapeutics, Inc.
Healthcare
|
Reduced | 1,283,979 | $40,727,813 | 0.84% | |
| COGT |
Cogent Biosciences, Inc.
Healthcare
|
Added | 1,000,000 | $38,490,000 | 0.79% | |
| CRVS |
Corvus Pharmaceuticals, Inc.
Healthcare
|
NEW | 2,491,539 | $36,451,215 | 0.75% | |
| DYN |
Dyne Therapeutics, Inc.
Healthcare
|
Reduced | 2,000,000 | $36,260,000 | 0.75% | |
| SLNO |
Soleno Therapeutics Inc
Healthcare
|
Added | 1,078,710 | $36,115,210 | 0.75% | |
| ACRS |
Aclaris Therapeutics, Inc.
Healthcare
|
NEW | 9,345,000 | $35,043,750 | 0.72% | |
| MANE |
Veradermics, Inc
Healthcare
|
NEW | 500,000 | $31,575,000 | 0.65% | |
| VSTM |
Verastem, Inc.
Healthcare
|
Held | 5,740,850 | $30,426,505 | 0.63% | |
| ENGN |
enGene Therapeutics Inc.
Healthcare
|
Held | 4,377,572 | $29,811,265 | 0.62% | |
| VRDN |
Viridian Therapeutics, Inc.\DE
Healthcare
|
Reduced | 1,393,944 | $27,265,544 | 0.56% | |
| XFOR |
X4 Pharmaceuticals, Inc
Healthcare
|
Added | 6,339,535 | $26,182,279 | 0.54% | |
| SLDB |
Solid Biosciences Inc.
Healthcare
|
NEW | 3,565,062 | $25,668,446 | 0.53% | |
| ENTA |
Enanta Pharmaceuticals Inc
Healthcare
|
Held | 1,956,867 | $24,715,230 | 0.51% | |
| APGE |
Apogee Therapeutics, Inc.
Healthcare
|
NEW | 285,000 | $23,988,450 | 0.49% | |
| KURA |
Kura Oncology, Inc.
Healthcare
|
NEW | 2,643,542 | $21,491,996 | 0.44% |
Covers the securities this platform tracks: U.S.-listed common stock and the put/call positions reported on it. A 13F can also report security types outside that coverage — preferred shares, bonds, warrants, untracked share classes — so the filing's own declared total can exceed the figures above. The source filing is linked at the top of this table.